LBL-058 / Leads Biolabs - LARVOL DELTA

LBL-058, A novel T cell engager conjugate (TEC) targeting DLL3 with dual tumor suppressive functions. (AACR 2025) - "Nowadays, many DLL3-targeting therapies are in development among them Tarlatamab, which is a T cell engager (TCE), has been approved by FDA for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy, at the same time several DLL3 targeting ADCs were also showing some promising results. LBL-058 has the potential to be a First-In-Class DLL3-targeted TCE ADC, which combines the anti-tumor properties of TCE and ADC, and shows a potent and durable anti-tumor activity and is expected to provide clinical benefits for the treatment of patients with SCLC."

Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3